Oral BGE-102 for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 Jun 2026: Trial started, NCT07656727
  2. 18 Jun 2026: Trial registered, NCT07656727

The trials

NCT07656727: A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

State
Under way
Phase
Phase 2
People
160 planned
Started
11 Jun 2026
Primary completion
30 Nov 2026
Arms
Arm A: BGE-102 Dose A, Arm B: BGE-102 Dose B, Arm C: BGE-102 Dose C
Results
None posted
  1. 11 Jun 2026: Trial started
  2. 18 Jun 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.